Patient access to orphan drugs in France
Abstract Background Since incentives were introduced to promote orphan drugs in Europe, several dozens of drugs have been registered at the European level. However, patient access on a national level remains very heterogeneous across Europe. This can be explained by healthcare organization and drug...
Main Authors: | Marion Bourdoncle, Blandine Juillard-Condat, Florence Taboulet |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-019-1026-4 |
Similar Items
-
Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022
by: Jia Liu, et al.
Published: (2023-03-01) -
Orphan drugs in Italy: availability and time-to-access at regional level
by: Maria Lucia Marino, et al.
Published: (2023-12-01) -
Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01) -
Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
by: ZHANG Shan, et al.
Published: (2023-04-01) -
Orphan drugs and rare diseases /
by: Pryde, David C., editor, et al.
Published: (2014)